Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred [0.03%]
广义和狭义表型算法的比较：性能特征及永生时间差异
Joel N Swerdel,Mitchell M Conover
Joel N Swerdel
Introduction: When developing phenotype algorithms for observational research, there is usually a trade-off between definitions that are sensitive or specific. The objective of this study was to estimate the performance characteristics of p...
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials [0.03%]
慢性肾脏病患者使用口服钾交换树脂的治疗效果更新：一项随机对照临床试验的系统评价
Jaclyn Gruver,Akram Al-Makki,Brian Shepler
Jaclyn Gruver
Hyperkalemia is a common electrolyte disorder in patients with chronic kidney disease (CKD) that increases in prevalence with the decline of glomerular fltration rate (GFR). Another risk of hyperkalemia is the use of renin-angiotensin-aldos...
Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs [0.03%]
勘误表：吸入药物药代动力学和生物等效性研究中呼出气冷凝液的应用
Nastaran Hashemzadeh,Elaheh Rahimpour,Abolghasem Jouyban
Nastaran Hashemzadeh
[This corrects the article DOI: 10.18433/jpps33121.]. Keywords: bioequivalence; exhaled breath condensate; i...
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada [0.03%]
HER2阳性转移性乳腺癌的三线治疗模式：对加拿大真实世界数据的回顾性分析
Karen Gambaro,Mélanie Groleau,Suzan McNamara et al.
Karen Gambaro et al.
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no standard treatment is specifically recommended. This study presents the first real-world analysis of third-line ...
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches [0.03%]
当前用于肝纤维化治疗的调查：在重新定位FDA已批准药物和其他新兴方法之间取舍
Omima S Mohammed,Hany G Attia,Bassim M S A Mohamed et al.
Omima S Mohammed et al.
Long-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Thus, continuous in...
Jing Guan,YiHui Zhao,Ting Wang et al.
Jing Guan et al.
Aplastic anemia (AA) is a bone marrow failure disease caused by T cell hyperfunction. Although the overall response rate has been improved by immunosuppressive therapy (IST) plus Eltrombopag, 30% of patients have either no response or relap...
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective [0.03%]
加拿大患者支持项目中的数据收集及其对真实世界证据生成的影响（作者视角）
Allison Wills,Arif Mitha,Winson Y Cheung
Allison Wills
Patient support programs (PSPs) offer a unique opportunity to collect real-world data that can contribute to improving patient care and informing healthcare decision making. In this perspective article, we explore the collection of data thr...
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study [0.03%]
右美托咪啶鼻喷剂用于颌面手术后首夜睡眠障碍的临床观察：单中心双盲随机对照试验
Ye Wang,Zibin Jin,Wenli Xu et al.
Ye Wang et al.
Purpose: Dexmedetomidine exerts a sedative effect by promoting the sleep pathway endogenously and producing a state similar to N2 sleep. This study aimed to study the efficacy and safety of dexmedetomidine nasal spray in the treatment of po...
Integration of real-world evidence from different data sources in health technology assessment [0.03%]
基于不同数据来源的真实世界证据在卫生技术评估中的整合
Pooyeh Graili,Jason R Guertin,Kelvin K W Chan et al.
Pooyeh Graili et al.
Real-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evi...
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database [0.03%]
新冠mRNA疫苗接种与IgA肾病相关性分析：基于日本药品不良事件报告数据库的一项研究
Hiroka Nakao,Takenao Koseki,Koki Kato et al.
Hiroka Nakao et al.
Purpose: Coronavirus disease 2019 (COVID-19) mRNA vaccines are used worldwide to prevent severe symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. IgA nephropathy (IgAN) is the most common form of glomerular...